INDOSAT
28.2.2023 11:55:38 CET | Business Wire | Press release
President Director and CEO of Indosat Ooredoo Hutchison (Indosat), Vikram Sinha, discussed the story of Indosat, the most successfully merger that empowers Indonesia. Indosat is the new world-class digital telecoms and internet company for Indonesia resulting from the merger of Indosat Ooredoo and Hutchison 3 Indonesia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005739/en/
Vikram Sinha, President Director and CEO of Indosat Ooredoo Hutchison (Photo: Business Wire)
During the roundtable discussion, Sinha highlighted that telco mergers often fail for various reasons, such as difficulty integrating different technologies and systems, regulatory hurdles, and challenges in retaining key personnel and customers. However, Indosat's successful merger has transformed the telecommunications industry and Indonesia's GDP growth.
Indonesia is one of the fastest-growing economies in the world and one of the most prominent digital economies in ASEAN. Digital adoption enables Indonesia to reduce the time to realize its long-term goal of achieving high-income status. Indosat, a digital telco with 100 million subscribers, is transforming rapidly to help drive the digital revolution in the country.
Sinha discussed how the merger of Indosat Ooredoo and Hutchison 3 Indonesia had exceeded all expectations for 2022, giving a positive outlook for Indonesia's market and the opportunity to grow in the telco industry. Indosat has an ongoing 9-quarter integration plan, and the realization of their synergies is running smoothly and has been completed ahead of the plan. Using Multi-Operator Core Networks (MOCN) technology, their network integration is targeted to be completed this quarter.
Indosat launched a research report titled Empowering Indonesia 2023, which reviews the pillars of Indonesia's digital economy and the role of technology in accelerating its future growth. The report shows that Indosat is the primary driver of the telecommunications industry and Indonesia's GDP growth, fueled by its solid growth in 2022.
Indosat's Full-Year 2022 Result shows a solid performance both financially and operationally. Total revenue increased by 48.9% YoY, EBITDA was recorded at Rp19,468.7 billion, and net profit for the year attributable to parent company owners was Rp4,723.4 billion, normalized net profit increased by 76.2% YoY. The company's cellular customers increased by 62.5% to 102.2 million for FY 2022.
"We have defied expectations and become the successful merger in the world. Indosat is not just good for the industry; it's good for Indonesia. We will continue to drive the digital revolution and create value for all our stakeholders," said Vikram Sinha, President Director and CEO of Indosat Ooredoo Hutchison.
About Indosat Ooredoo Hutchison
Indosat Ooredoo Hutchison (IDX: ISAT)’s vision is to become the most preferred digital telco of Indonesia. Through its world-class digital telecom services and preeminent network, Indosat Ooredoo Hutchison strives to connect and empower every Indonesian. Jointly controlled by Ooredoo Group and CK Hutchison, Indosat Ooredoo Hutchison was formed through the merger of PT Indosat Tbk and PT Hutchison 3 Indonesia in 2022.
Website: www.IOH.co.id
YouTube: https://www.youtube.com/channel/UChs2x7pZ2D8UgHz9cgrn3sQ
Facebook: https://www.facebook.com/indosat
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005739/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom